Form 4: Mirum Pharmaceuticals Director Equity Grant

Director William Fairey received an equity grant of stock options and deferred stock units from Mirum Pharmaceuticals.

Summary

• Director William Fairey was granted 3,772 stock options with an exercise price of $101.00.
• Director William Fairey was granted 1,980 deferred stock units (DSUs).
• Both the stock options and DSUs vest on the first anniversary of the grant date (June 15, 2027), or upon the date of the 2027 annual stockholder meeting, whichever occurs first.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The issuance of equity results in minor dilution to existing shareholders.

Risks

• Market volatility affecting the value of the granted equity instruments.
• Potential for future dilution if additional equity-based compensation is issued to directors and employees.

Future Outlook

The equity grants are subject to standard vesting schedules tied to the 2027 annual stockholder meeting or the first anniversary of the grant date.

Industry Context

StockSavvy.ai notes that equity grants to non-employee directors are standard corporate governance practice in the biotechnology sector to ensure board members maintain a vested interest in company performance.

Comparison to Industry Standards

• The use of a mix of stock options and deferred stock units is consistent with standard compensation packages for directors in mid-cap pharmaceutical companies.
• Vesting periods tied to annual meetings are common practice to ensure director retention through the annual cycle.

Corporate Governance

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity.

Next Steps

• Vesting of equity grants on the earlier of the first anniversary of the grant date or the 2027 annual stockholder meeting.

Key Dates

Keywords

Mirum Pharmaceuticals, MIRM, Director Compensation, Equity Grant, Form 4, Insider Transaction